Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
NCT ID: NCT07316101
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2026-03-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Does the device reduce the total time the surgeon has to stop because the lens fogs up?
* What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used?
Researchers will compare the anti-fog device to the usual "water-squirt" method to see if the device works better.
Participants will:
* Have either the device or the usual water method applied during their planned pituitary surgery
* Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7
* Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection
NCT04938401
Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery
NCT03773705
Free Middle Turbinate Flap for Repair of Low Flow Cerebrospinal Fluid Leak
NCT04784169
To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery
NCT06221020
Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture
NCT02299830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia.
The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana.
Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensation.
Two side ports provide continuous low-pressure (-5 cmH₂O) suction of any blood or fluid, keeping the surgical field dry.
The device remains in place for the entire operation and is removed before nasal packing. No extra incisions or sutures are required.
Anti-fog suction device-a 4 Fr multi-channel silicone catheter
A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia.
The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana.
Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensation.
Two side ports provide continuous low-pressure (-5 cmH₂O) suction of any blood or fluid, keeping the surgical field dry.
The device remains in place for the entire operation and is removed before nasal packing. No extra incisions or sutures are required.
Control group
Standard care: whenever the lens fogs, the scrub nurse withdraws the endoscope and irrigates its tip with 5-10 ml of 37 °C sterile saline from a 20 ml syringe. This manoeuvre is repeated as often as necessary (average 10-15 times per case).
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-fog suction device-a 4 Fr multi-channel silicone catheter
A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia.
The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana.
Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensation.
Two side ports provide continuous low-pressure (-5 cmH₂O) suction of any blood or fluid, keeping the surgical field dry.
The device remains in place for the entire operation and is removed before nasal packing. No extra incisions or sutures are required.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pre-operative MRI/CT diagnosis of pituitary adenoma or craniopharyngioma ≤ \*3 cm without extensive skull-base invasion
* Scheduled for elective endoscopic endonasal transsphenoidal resection
* ASA physical status I-III
* Able and willing to give written informed consent and comply with follow-up
Exclusion Criteria
* Active nasal or systemic infection (WBC \> 10 × 10⁹/L, CRP ≥ 10 mg/L)
* Known intracranial infection or ongoing CSF leak
* Coagulopathy (PT \> 14 s or APTT \> 45 s) or anticoagulation that cannot be stopped ≥ 7 days
* Allergy to silicone or medical-grade plastics
* Planned combined transcranial or transorbital approach
* Pregnancy or breastfeeding
* Psychiatric or cognitive disorder precluding informed consent or follow-up
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhigang Lan
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WestChinaH-HX-2025-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.